Tailored antiplatelet drugs to prevent another stroke in non-cardioembolic ischemic stroke
Tests tailored antiplatelet drug choices against usual care in adults after ischemic stroke.
Key facts
- Who runs it
- Azienda Usl di Bologna
- Where
- Italy3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Personalized Antiplatelet Therapy to Prevent Recurrent Cardiovascular Events in After Ischemic Stroke
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 1,506 people, planned
- Starts
- Dec 2026
- Expected to end
- Jun 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Acetylsalicylic acid (ASA)/aspirin 100 mg daily
- Clopidogrel 75 mg daily
- Ticlopidine 250 mg twice daily
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Aged ≥18 years old
- Males and females
- Non-cardioembolic ischemic stroke within the previous 14 days
- Starting or continuing secondary prevention with single or dual antiplatelet therapy after the index stroke
- Written informed consent
Who cannot take part
- Concurrent need for anticoagulation for any indication
- Contraindication to study drugs
- Indications to perform carotid revascularization surgery
- Participation in a clinical trial in which an investigational drug was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer
- Active or previous recurrent peptic ulcer and/or gastric/intestinal bleeding, or other types of bleeding such as cerebrovascular hemorrhage
- Methotrexate used at doses equal to or greater than 15 mg/week. Combination with other potentially myelotoxic drugs. Subjects with or who have had leukopenia, thrombocytopenia, or agranulocytosis
- Known hypersensitivity to aspirin, clopidogrel or ticlopidine, or to any of the excipients
- History of asthma induced by the administration of acetylsalicylates or substances with a similar activity, especially nonsteroidal anti-inflammatory drugs
- Bleeding diathesis; coagulation disorders such as hemophilia and thrombocytopenia
- Severe hepatic impairment
- Severe renal impairment
- Uncontrolled severe cardiac failure
- Pregnancy and breastfeeding; WOCBP not using acceptable contraception during the trial period (combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device [IUD], intrauterine hormone-releasing system [IUS], bilateral tubal occlusion. vasectomised partner, sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The TAILOR study aims to determine whether personalized antiplatelet therapy can reduce the risk of recurrent major cardiovascular events in patients who have experienced (a non-cardioembolic ischemic stroke).
Read full original descriptionShow less
Antiplatelet medications, such as aspirin and clopidogrel, are commonly prescribed to prevent stroke recurrence. However, some patients do not respond adequately to these medications and may remain at increased risk of further cardiovascular events.
The study will compare two approaches to antiplatelet therapy: standard care, in which medications are prescribed according to current clinical practice, and personalized care (tailored care), in which treatment is adjusted based on a blood test measuring how effectively the medication inhibits platelet activity.
Participants will be randomly assigned to one of these two treatment strategies and followed for 12 months.
The main hypothesis is that tailoring antiplatelet therapy according to individual platelet response will be more effective than standard care in preventing recurrent ischemic stroke, myocardial infarction, or cardiovascular death. The study will also explore potential differences in treatment response between women and men.
The 2 groups in the trial
- Usual careExisting treatment, for comparison
Participants in this arm will continue the antiplatelet therapy (aspirin or clopidogrel) started after the index stroke, according to usual care, independently of platelet aggregation test results. Platelet function testing is performed in all participants, but results are not disclosed to treating physicians in this arm. Patients receiving short-term DAPT will continue, at the end of the 10-day run-in period, with the single antiplatelet agent indicated by usual care (aspirin or clopidogrel), regardless of platelet aggregation test results.
Treatment: Acetylsalicylic acid (ASA)/aspirin 100 mg daily, Clopidogrel 75 mg daily, and Ticlopidine 250 mg twice daily
- Tailored careTreatment being tested
Based on platelet aggregation test results (Multiplate ASPI and ADP tests), antiplatelet therapy will be tailored as follows: 1. If taking aspirin and the test confirms responsiveness, aspirin is continued. 2. If taking clopidogrel and the test confirms responsiveness, clopidogrel is continued. 3. If taking aspirin and the test shows non-responsiveness, therapy is switched to clopidogrel or ticlopidine. 4. If taking clopidogrel and the test shows non-responsiveness, therapy is switched to aspirin or ticlopidine. Patients with an indication to short-term dual antiplatelet therapy (DAPT; minor stroke with NIHSS ≤3) will undergo a 10-day run-in period and then continue with single antiplatelet therapy: patients due to continue aspirin will switch to clopidogrel if non-responders to aspirin; patients due to continue clopidogrel will switch to ticlopidine if non-responders to clopidogrel.
Treatment: Acetylsalicylic acid (ASA)/aspirin 100 mg daily, Clopidogrel 75 mg daily, and Ticlopidine 250 mg twice daily
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Tailored Antiplatelet Secondary Prevention in Non-cardioembolic Ischemic Stroke: a Phase IV Gender-stratified Randomized Controlled Trial (TAILOR Trial)
- Plain-language title
- Tailored antiplatelet drugs to prevent another stroke in non-cardioembolic ischemic strokeGenerated from the registry record. The registry title is the official one.
- Record updated
- 17 November 2026